Dec 15 (Reuters) - Australian Clinical Labs Ltd (ACL) :
- INTENTION TO WITHDRAW TAKEOVER OFFER FOR HEALIUS
- NO LONGER BELIEVES OFFER CONSIDERATION OF 0.74 ACL SHARES FOR EACH HEALIUS SHARE FAIRLY REFLECTS RELATIVE CONTRIBUTION
- ACL BOARD IS CONCERNED BASED ON 1H GUIDANCE THAT HEALIUS IS AT RISK OF A SIGNIFICANT STATUTORY NPAT LOSS IN 1H FY24
- CONTINUES TO BELIEVE BENEFITS OF A MERGER BETWEEN ACL AND HEALIUS ARE COMPELLING
- ALSO NOTES THAT ACCC TODAY ANNOUNCED THAT IT OPPOSES COMBINATION OF ACL AND HEALIUS
- REMAINS OPEN TO A MERGER BETWEEN CO & HEALIUS
- ACL BOARD INTENDS TO CLOSELY MONITOR PERFORMANCE OF HEALIUS IN COMING MONTHS & REMAINS OPEN TO MERGER BETWEEN 2 COMPANIES
- CONCERNED BASED ON 1H GUIDANCE THAT HEALIUS IS AT RISK OF A SIGNIFICANT STATUTORY NPAT LOSS IN 1H FY24
- DECISION BY ACCC GIVES CO ABILITY TO CHALLENGE ACCC'S POSITION DIRECTLY IN COURT IF IT MAKES A NEW OFFER IN NEAR FUTURE
Add to My Watchlist
What is My Watchlist?
